Načítá se...
Introducing Vernakalant into Clinical Practice
Vernakalant is an antiarrhythmic drug licensed for the pharmacological cardioversion of recent onset AF. Randomised clinical trials, backed up by real-world experience, have confirmed its efficacy at restoring sinus rhythm. Vernakalant can be administered simply with a short time to action, facilita...
Uloženo v:
| Vydáno v: | Arrhythm Electrophysiol Rev |
|---|---|
| Hlavní autoři: | , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Radcliffe Cardiology
2019
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6434499/ https://ncbi.nlm.nih.gov/pubmed/30918671 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.15420/aer.2018.71.2 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|